secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immix Biopharma, Inc. (IMMX)
CIK:        0001873835
Form:       8-K
Filed at:   2026-03-25T23:59:59+00:00
Accession:  0001493152-26-012721
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immix Biopharma ups ATM offering to $100M from $50M
---------------------------------------------------

- Increased max aggregate offering price under ATM agreement from $50M to $100M.
- Amendment updates registration statement to Form S-3 (File 333-292665).
- Sales agent commission remains 3% of gross proceeds; $50K expense cap.
- Company may sell shares at market prices from time to time; no minimum.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873835/000149315226012721/0001493152-26-012721-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873835/000149315226012721/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-012721

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer